Compare ARES & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARES | WST |
|---|---|---|
| Founded | 1997 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7B | 25.6B |
| IPO Year | 2014 | 2004 |
| Metric | ARES | WST |
|---|---|---|
| Price | $120.83 | $353.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 7 |
| Target Price | $165.50 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 2.0M | 682.3K |
| Earning Date | 05-01-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.87% | 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 1.92 |
| Revenue | ★ $4,755,618,000.00 | $2,886,900,000.00 |
| Revenue This Year | N/A | $6.76 |
| Revenue Next Year | $17.59 | $6.22 |
| P/E Ratio | ★ $78.35 | $184.26 |
| Revenue Growth | ★ 28.86 | 1.95 |
| 52 Week Low | $95.80 | $221.50 |
| 52 Week High | $195.26 | $367.66 |
| Indicator | ARES | WST |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 57.24 |
| Support Level | $119.40 | $349.41 |
| Resistance Level | $123.46 | $367.66 |
| Average True Range (ATR) | 4.19 | 7.62 |
| MACD | 0.85 | -1.51 |
| Stochastic Oscillator | 70.34 | 28.00 |
Ares Management is one of the world's largest alternative-asset managers, with $622.5 billion in total assets under management, or AUM, including $384.9 billion in fee-earning AUM, at the end of 2025. The company has four main business segments: credit strategies ($406.9 billion in total AUM and $249.8 billion in fee-earning AUM), private equity, ($25.3 billion/$14.4 billion), real estate/real assets ($139.1 billion/$84.1 billion), and other alternatives ($51.2 billion/$36.6 billion). The firm primarily serves institutional investors (80% of AUM) and high-net-worth individuals (20%). Ares operates through more than 35 offices in over 15 countries around the globe.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.